Gilead Buys Arresto For $225 Million | January 3, 2011 Issue - Vol. 89 Issue 1 | Chemical & Engineering News
Volume 89 Issue 1 | p. 12 | Concentrates
Issue Date: January 3, 2011

Gilead Buys Arresto For $225 Million

Department: Business
Keywords: monoclonal antibody, biotechnology, cancer

Gilead Sciences will acquire Arresto Biosciences, a development-stage biotech company in Palo Alto, Calif., that focuses on fibrotic diseases and cancer. Gilead will pay $225 million and make unspecified future payments based on sales achievements. Arresto’s lead drug candidate, the monoclonal antibody AB0024, is in Phase I trials for the treatment of idiopathic pulmonary fibrosis (IPF) and advanced solid tumors. The acquisition is the first foray for Gilead, historically focused on small molecules, into the development of monoclonal antibodies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment